Ken Griffin Glycomimetics Inc Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.24 - $3.04 $216 - $2,736
900 Added 5.33%
17,800 $4,000
Q1 2024

May 15, 2024
BUY
$2.55 - $3.49 $15,809 - $21,638
6,200 Added 57.94%
16,900 $50,000
Q4 2023

Feb 14, 2024
BUY
$1.13 - $2.54 $12,090 - $27,178
10,700 New
10,700 $25,000
Q2 2023

Aug 14, 2023
SELL
$1.21 - $2.08 $8,107 - $13,936
-6,700 Reduced 35.26%
12,300 $21,000
Q1 2023

May 15, 2023
BUY
$1.25 - $4.05 $23,000 - $74,520
18,400 Added 3066.67%
19,000 $23,000
Q4 2022

Feb 14, 2023
BUY
$0.57 - $3.03 $341 - $1,817
600 New
600 $1,000

Others Institutions Holding GLYC

# of Institutions
35
Shares Held
17.7M
Call Options Held
0
Put Options Held
0
View Full List

About GLYCOMIMETICS INC

GLYC Quotes by TradingView
  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $14.2M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email